BIORESEARCH UPDATE NEWSLETTER #7 Patent of Amycenone® (Yamabushi-take Standardized Extract) Registered in Japan ~ Potentiality increases to use proprietary extract to improve brain function~

April 3, 2013

Amycenone®, a proprietary extract developed from a mushroom called Lion’s Mane (Hericium erinaceus), has been awarded a patent in Japan.  Its patent in the U.S. is pending.

Amyloban®3399, a dietary supplement containing Amycenone® as an active ingredient, has been widely used and a number of clinical cases have also been reported for its role in certain conditions such as benign or mild dementia, snoring, sleep apnea, low quality of sleeping, juvenile apathy syndrome and schizophrenia.  Presentations on its clinical and laboratory studies have been made recently and a numbe r of articles on the original studies have been published on medical journals. The efficacy of the extract as introduced in such presentations and papers is persuasive as the active ingredients contained in the extract are explicitly identified and quantified, and the manufacturer has established the method of standardization to guarantee the actual content of these ingredients in their extract product.

Amycenone® has a patented ingredient that is confirmed to have an activity to increase the production of Nerve Growth Factor (NGF) in the brain as well as another ingredient to maintain healthy brain function by preventing nerve cell death by toxic amyloid β-peptide that is believed to be the cause of Alzheimer’s-type dementia. Furthermore, researchers are focusing on its potential activity of influencing the level of consciousness in the brain. Some promising results on the study may be coming soon.

So far, no significant adverse effects have been reported on the clinical uses of Amycenone®.